Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComm's CRO Preferred Program
Posted on: Tuesday, 18 August 2009, 09:26 CDT
FORT LAUDERDALE, Fla., Aug. 18 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that it has been selected by Amarex, a Mid-Atlantic based Contract Research Organization (CRO) to provide eClinical solutions for an upcoming Phase III trial investigating the use of a medical device for wound healing. The study will be conducted at over 30 sites and will recruit up to 300 patients over the course of two years. Amarex also joins OmniComm's CRO Preferred Program, which will allow them to offer OmniComm's flexible, robust electronic data capture solution, TrialMaster(TM), to their clients. Amarex also benefits from the CRO Program's distinct advantages that include fixed pricing with no hidden fees, complete sales and marketing support, and dedicated hosting services in OmniComm's world class hosting facility.
"We are honored that such a well-reputed CRO like Amarex has joined our CRO Preferred Program and look forward to working closely with them on this high profile study," remarked Stephen Johnson, COO of OmniComm Systems. "Amarex has a reputation for delivering superior service to their customers - a commitment that we share here at OmniComm. The combination of our products and services will be beneficial for both companies, but more importantly will offer our customers the solutions they need to bring life saving drugs and devices to market."
About Amarex Clinical Research
Amarex Clinical Research, Inc. is a global clinical research organization supplying a full range of clinical trial services to the pharmaceutical, biotech, and medical device communities. Amarex has managed studies in a breadth of therapeutic areas in Phase I through Phase IV study development. The company employs approximately 50 personnel in its offices located in the United States, and reaches clients worldwide through its Internet-based data collection and reporting capabilities. Amarex is headquartered in Germantown, MD. For more information, please visit the company's Web site at http://www.amarexcro.com.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Catherine Lemercier Gary Nash OmniComm Systems, Inc. CEOcast, Inc. for OmniComm 954-473-1254 Extension 283 212-732-4300 clemercier@omnicomm.com gnash@ceocast.com Stephen Johnson 954-377-1726SOURCE OmniComm Systems, Inc.
Source: PR Newswire
Related Articles
- Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies
- Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says
- HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research
- Chiltern Acquires Brazil-Based Clinical Research Organization Vigiun
- ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities
- Sierra Systems' Health Care Practice Accelerates Market Momentum With High-Value Consulting and Systems Integration Services
- Marshfield Clinic Research Team Uses Affymetrix DMET Solution to Discover Genetic Variant Affecting Warfarin Metabolism in Patients
- Hadasit Announces Hadassah Hospital's New Clinical Research Center
- Lifetree Clinical Research(R) to Highlight Services at the BIO International 2007 Convention May 6-9, Boston, MA
 |
 |
User Comments (0)
RSS Feeds